Department of Emergency, The First People's Hospital of Linping District, Hangzhou, China.
Department of Neurology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China.
J Int Med Res. 2024 Sep;52(9):3000605241276489. doi: 10.1177/03000605241276489.
We conducted a systematic review and meta-analysis to evaluate the clinical effectiveness and safety of riluzole to treat neurodegenerative dyskinesia in patients, using the Cochrane collaboration guidelines.
We searched databases including Medline, Embase, and Cochrane without any language filters. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was used as a guideline, and the study protocol was registered in PROSPERO (CRD42022354627).
Eleven studies involving 1376 patients were included. There was a significant overall effect of riluzole on changes in motor function scores. However, the level of heterogeneity was = 74%. In the subgroup analyses, there were no significant effects of riluzole on motor scores in hereditary ataxia, Parkinson's disease, or Huntington's disease. In the sensitivity analysis, there were no significant effects of riluzole on motor function scores. Furthermore, there were no significant differences in adverse events between the riluzole and placebo groups.
Although riluzole may not have significant efficacy for improving motor function in neurodegenerative dyskinesia syndromes compared with placebo, it seems to have an acceptable safety profile. Moreover, it may be effective for hereditary ataxia syndromes, although there was a relatively small effect size and limited quality of evidence.
我们按照 Cochrane 协作组织的指南，进行了一项系统评价和荟萃分析，以评估利鲁唑治疗神经退行性运动障碍患者的临床疗效和安全性。
我们检索了 Medline、Embase 和 Cochrane 等数据库，未设置任何语言限制。本研究遵循 Preferred Reporting Items for Systematic Reviews and Meta-Analyses（PRISMA）声明，并在 PROSPERO（CRD42022354627）中进行了方案注册。
共纳入 11 项研究，涉及 1376 例患者。利鲁唑对运动功能评分的变化有显著的总体影响。然而，异质性水平为 74%。亚组分析显示，利鲁唑对遗传性共济失调、帕金森病或亨廷顿病患者的运动评分没有显著影响。敏感性分析显示，利鲁唑对运动功能评分也没有显著影响。此外，利鲁唑组与安慰剂组在不良反应方面无显著差异。
虽然与安慰剂相比，利鲁唑在改善神经退行性运动障碍综合征的运动功能方面可能没有显著疗效，但它似乎具有可接受的安全性。此外，它可能对遗传性共济失调综合征有效，尽管疗效的效应量较小，且证据质量有限。
